Stoke Therapeutics, Inc.
STOK· Nasdaq
Released Aug 8, 2022, before the open
10-Q filed Aug 8, 2022, 39 days after period end · 0001564590-22-028440
| Metric | Q2 2022 | Q2 2021 | Q2 2020 | Q2 2019 |
|---|---|---|---|---|
| Revenue | $3.23M | — | — | — |
| Net Income | -$24.65M | -$21.97M | -$12.96M | -$7.82M |
| EPS Diluted |
Stoke Therapeutics, Inc. · CIK 1623526 · Engraved from SEC EDGAR
| -$0.63 |
| -$0.60 |
| -$0.39 |
| -$1.54 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.